MoleculeMind (分子之心), an AI protein design platform founded by pioneering computational biologist Pro...
The AMW Read
Large Series A for a non-Western player claiming state-of-the-art protein prediction and industrial platform; updates the player map for AI in drug discovery and biomanufacturing, and exemplifies the pattern of moving from prediction to full-stack commercial platforms.
MoleculeMind (分子之心), an AI protein design platform founded by pioneering computational biologist Professor Xu Jinbo (许锦波), has raised over $100 million across a Series A series. The round includes a diverse investor roster: Lanqiao Capital, Pudong Venture Capital, COFCO Emerging Industry Fund, Fortune Capital (Fosun), and existing backers Cathay Biotech and Xinwan Capital. The funding signals a strategic bet on AI-driven protein engineering as foundational infrastructure for biomanufacturing and drug discovery.
Why it matters: MoleculeMind’s raise injects significant capital into the AI for Science (AI4S) segment at a moment when the market is demanding industrial-grade validation over academic benchmark scores. The company’s flagship platform MoleculeOS integrates its NewOrigin (Darwin) multimodal protein foundation model with a wet-lab feedback loop, claiming over 90% hit rates on 12 real clinical targets and solutions for notoriously difficult targets like GPCR and TNFα. This mirrors a broader pattern in Segment 06 (Healthcare/Bio): the shift from “prediction-only” AI tools to full-stack “design-verify-produce” platforms that can command enterprise contracts and recurring revenue. The presence of strategic investors from food (COFCO), materials (Cathay Biotech), and pharma indicates that the platform’s industrial biotech applications — enzyme engineering, material optimization — are seen as equally valuable as therapeutic design.
Expert take: MoleculeMind’s ability to attract both financial and strategic capital in a cautious funding environment underscores a growing conviction that AI-native bioengineering platforms can become a new category of industrial infrastructure. The claim that the platform’s MMFold model outperforms AlphaFold 3 on antibody-antigen interfaces, if validated, would position the company as a rare non-Western challenger in the most commercially relevant subset of protein prediction. The key risk is execution: transforming scientific breakthroughs into scalable, repeatable commercial workflows that sustain the high customer retention the company reports. #AIProteins #BioEngineering #DrugDiscovery #AISeriesA #IndustrialBiotech #MoleculeMind